Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 12Colorectal Neoplasms 9Neoplasm Metastasis 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Solid Tumors Harboring a BRAF V600 Mutation 1Skin Neoplasms 1Skin Diseases 1Recurrence 1Pancreatic Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1Advanced BRAF Mutant Cancers 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × encorafenib × Clear all
NCT03898908 2025-05-21

EBRAIN-MEL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed
48 enrolled 24 charts
CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡